Abstract
Reports of COVID-19 prevalence through national statistics, community surveys and targeted testing at places of work or study have guided national and institutional responses to the pandemic. The University of Edinburgh established a mass testing programme, TestEd, for detection of COVID-19 in asymptomatic staff and students who are studying or working on campus. The study has tested more than 100,000 samples with more than 170 confirmed positive results. Since the introduction of a change in policy in England and the UK devolved nations in early January 2022, to limit eligibility for PCR testing in the community to those with symptoms, we have noticed a divergence between the reports in Scottish and UK-wide prevalence, and the magnitude and frequency of positive results in the University datasets. While the national UK-wide and Scottish case figures show declining or stable prevalence, University case reports have risen more than five-fold since early December 2021 and continue to rise. These observations could be important in the face of future variants of concern and emphasise the need for continued access to high sensitivity PCR testing and other forms of surveillance.
Competing Interest Statement
Mixed competing interests. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: TA undertakes consultancy for BioCaptiva Ltd (unrelated to present manuscript). TA received support for attending meetings and/or travel from Global Engage and Oxford Global. TA has a patent filed in the liquid biopsy field unrelated to the present study. TA participates in the Scottish Genomics Leadership Group Advisory Board. TA was a panel member of the European Research Council (2018 to 21). TA is a shareholder of BioCaptiva Ltd (unrelated to present work). LB serves as interim chief social policy adviser to the Scottish Government and is a member of the Chief Medical Officers (Scotland) Advisory Group on Covid19.
Funding Statement
The study was funded by the University of Edinburgh and by UKRI Research Grant MR/W006243/1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Edinburgh Medical School Research Ethics Committee of University of Edinburgh gave ethical approval for this work (EMERC21).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
